Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 selinexor monotherapy in JAK inhibitor-naive myelofibrosis with moderate thrombocytopenia
MOH_2024-07-09_013272Phase 2Not yet recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in myelofibrosis (MF) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Not reported. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2024-07-09_013272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-07-09_013272.